Mechanical contraction to guide CRT left-ventricular lead placement instead of electrical activation in myocardial infarction with left ventricular dysfunction: An experimental study based on non-invasive gated myocardial perfusion imaging and invasive electroanatomic mapping

在心肌梗死合并左心室功能障碍的情况下,采用机械收缩而非电激活来引导CRT左心室导线植入:一项基于非侵入性门控心肌灌注显像和侵入性电解剖标测的实验研究。

阅读:1

Abstract

BACKGROUND: Whether the region of the latest electrical activation (LEA) corresponds with the segment of the latest mechanical contraction (LMC) in ischemic cardiomyopathy (ICM) is uncertain. We aimed to investigate the relationship between the left-ventricular (LV) viable segments with LEA and with LMC after myocardial infarction (MI) and analyze the acute hemodynamic responses (dP/dt(max)) after cardiac resynchronization therapy (CRT) pacing at different LV sites. METHODS AND RESULTS: Bama suckling pigs (n = 6) were subjected to create MI models. Both gated myocardial perfusion imaging (GMPI) and electroanatomic mapping (EAM) were performed successfully before MI and 4 weeks after MI. LMC was assessed by phase analysis of GMPI, while LEA was evaluated by EAM. The dP/dt(max) was measured before CRT and when the CRT LV electrode was implanted in viable segments of LMC, viable segments of lateral wall and scar, respectively. The viable segments of LEA were consistent with the sites of LMC for five in six cases. The dP/dt(max) increased significantly compared with that before CRT when the CRT LV electrode was implanted in viable segments of LMC (1103.33 ± 195.76 vs 717.83 ± 80.74 mmHg·s(-1), P = .001), which was also significantly higher than in viable segments of lateral wall (751.17 ± 105.62 mmHg·s(-1), P = .000) and scar (679.50 ± 60.87 mmHg·s(-1), P = .001). CONCLUSIONS: Non-invasive GMPI may be a better option than invasive EAM for guiding LV electrode implantation for CRT in ICM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。